The Use of Image Fusing in the Deployment of a 7-plex Immunofluorescent Assay
THE USE OF IMAGE FUSING IN THE DEPLOYMENT OF A 7-PLEX IMMUNOFLUORESCENT ASSAY
Date: 27 April 2020
Time: 8:00 – 9:00 PST | 11:00 – 12:00 EST | 16:00 – 17:00 GMT
Location: Webinar
Summary
In lieu of our participation in the now cancelled 2020 AACR Conference, Indica Labs are pleased to bring you webinar presentations from two of our esteemed customers in oncology research and drug discovery, David Krull from GlaxoSmithKline and Dr. David Reiss from Bristol Meyers Squibb, who will present on April 27th and 28th, respectively.
Please join us to hear about how Indica Labs image analysis software and pharma services are being used within their organizations to advance oncology drug development.
PLEASE NOTE you will need to register separately for each webinar presentation if you wish to attend both events. Webinar recordings will be sent to all registered delegates at the conclusion of the webinar series.
Recent developments multiplexing immunofluorescent assays have made it possible to detect several antibody targets in a single tissue section. This is enabled without the use of secondary antibodies or tyramide signal amplification techniques. This webinar will present a workflow employing DNA barcoded antibodies in the InSituPlex technology from Ultivue. The method, in brief, involves the use of two panels of markers that are applied in two rounds of staining with an imaging step after each. The resulting images are then fused, using HALO, to produce a single multiplex image. Further processing is performed in HALO to identify the specific phenotypes of labeled cells within tumor sections. Using this technology and workflow, we were able to detect 7 markers in same tissue section, which significantly expanded our capability to understand the expression and distribution of the immune cells in these tumors.
Presenter
David Krull
Manager & GSK Fellow, Cellular Biomarkers, GlaxoSmithKline
Manager & GSK Fellow, Cellular Biomarkers, GlaxoSmithKline
David Krull is a scientific leader and histotechnology subject matter expert at GlaxoSmithKline. He has over 30 years of experience in drug development and currently supports tissue biomarker assays for clinical trials.